CorMedix (CRMD) Non-Current Deferred Tax Liability (2025)
CorMedix's (CRMD) quarterly Non-Current Deferred Tax Liability came in at $144.6 million in Q4 2025, little changed quarter-over-quarter from $144.5 million in Q3 2025.
CorMedix (CRMD) Non-Current Deferred Tax Liability (2025) Analysis & Trends
CorMedix has disclosed Non-Current Deferred Tax Liability across 1 years of filings, most recently posting $144.6 million for Q4 2025.
- Non-Current Deferred Tax Liability for Q4 2025 came in at $144.6 million, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $144.6 million (changed N/A YoY), and the FY2025 annual result was $144.6 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability came in at $144.6 million for Q4 2025 at CorMedix, roughly flat from $144.5 million in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $144.6 million in Q4 2025 to a low of $144.5 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | CorMedix | 631,378.03 | -154.57 Mn | 107.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 144.63 Mn |
| Dec 31, 2025 | 144.63 Mn |
| Sep 30, 2025 | 144.53 Mn |
| Sep 30, 2025 | 144.53 Mn |